SCHEMBL4033509

SCHEMBL4033509

Cc1ccc(CC=O)nc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.43
CCR5 P51681 1/20 0.43
CCR8 P51685 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
NOS3 P29474 1/20 0.40
NOS2 P35228 1/20 0.40
MAPT P10636 2/20 0.37
RAB9A P51151 1/20 0.37
DAO P14920 1/20 0.37
CYP2A6 P11509 2/20 0.35
CYP3A4 P08684 1/20 0.35
KDM4E B2RXH2 4/20 0.35
PDE10A Q9Y233 1/20 0.35
HTR1A P08908 5/20 0.34
ALDH1A1 P00352 2/20 0.33
ADRA2A P08913 2/20 0.33
ADRA2B P18089 2/20 0.33
ADRA2C P18825 2/20 0.33
PLAU P00749 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30361378 1.00 CCR1 (0.43) CCR1CCR5CCR8HDAC6NOS3
Hydrochloric Acid SCHEMBL247415 0.98 CCR1 (0.41) CCR1CCR5CCR8HDAC6NOS3
SCHEMBL6197859 0.80 CCR1 (0.40) CCR1CCR5CCR8HDAC6NOS3
SCHEMBL7242158 0.79 CCR1 (0.43) CCR1CCR5CCR8HDAC6NOS3
SCHEMBL9003882 0.76 CCR1 (0.40) CCR1CCR5CCR8HDAC6NOS3
SCHEMBL622904 0.76 HRH3 (0.46) MAPTRAB9ACYP3A4KDM4EALDH1A1
SCHEMBL3021010 0.76
SCHEMBL4599552 0.75 CA12 (0.39) KDM4EADRA2AADRA2BADRA2C
SCHEMBL19555364 0.75 ESR1 (0.44)
SCHEMBL622260 0.75 GBA1 (0.41) MAPTRAB9AKDM4EALDH1A1ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230133132-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-05-04 US disclosed
WO-2012162468-A1 THIAZOL DERIVATIVES AS PRO -MATRIX METALLOPROTEINASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2012-11-29 WO disclosed
US-8148371-B2 Adenine compound and use thereof DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-04-03 US disclosed
US-20100256118-A1 NOVEL ADENINE COMPOUND AND USE THEREOF DAINIPPON SUMITOMO PHARMA CO.,LTD. (JP) 2010-10-07 US disclosed
US-7754728-B2 Adenine compound and use thereof DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-13 US disclosed
EP-1613613-A4 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC (CA) 2009-03-25 EP disclosed
US-20080146811-A1 Compounds and Methods For Treatment of Thrombosis DAIICHI ASUBIO MEDICAL RESEARCH LABORATORIES LLC 2008-06-19 US disclosed
WO-2007015929-A2 EPOTHILONE ANALOGUES UNIVERSITY OF TOLEDO (US) 2007-02-08 WO disclosed
EP-1613613-A2 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC. (CA) 2006-01-11 EP disclosed
WO-2004091518-A2 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC. (CA) 2004-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256118-A1 NOVEL ADENINE COMPOUND AND USE THEREOF ADORA1, P2RY10, HRH4 CCR1 438/4885CCR5 563/4885CCR8 502/4885
US-20080146811-A1 Compounds and Methods For Treatment of Thrombosis F2, SERPINC1, PLAT CCR1 784/4885CCR5 1400/4885CCR8 1696/4885
US-20230133132-A1 NAMPT MODULATORS NAMPT, MC4R, SIRT1 CCR1 4148/4885CCR5 3683/4885CCR8 4238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.